BioPharmSignal logoBioPharmSignal

Biotech News

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

Acumen Pharmaceuticals (ABOS)Acumen PharmaceuticalsEarnings

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report third quarter financial results on Monday, Oct. 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

Related news

ABOSAcumen Pharmaceuticals2026-08-05 20:00 EST

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

ABOSAcumen Pharmaceuticals2026-08-12 11:00 EST

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

SUPNSupernus2026-10-19 12:30 EST

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

TNXPTonix Pharmaceuticals2026-08-10 11:00 EST

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

XERSXeris Pharmaceuticals2026-10-22 12:00 EST

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

ALKSAlkermes plc2026-10-20 20:00 EST

Alkermes to Report Third Quarter Financial Results on November 3, 2026

HRMYHarmony Biosciences2026-10-20 12:05 EST

Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

AXSMAxsome2026-10-07 11:00 EST

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

NBIXNeurocrine Biosciences2026-10-12 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

TEVATeva Pharmaceutical Industries2026-09-23 20:45 EST

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

View all latest news

Acumen Pharmaceuticals

Alzheimer’s Disease Antibody Company Acumen Pharmaceuticals develops therapies targeting soluble amyloid-beta oligomers, which are believed to contribute directly to synaptic dysfunction in Alzheimer’s disease. Sabirnetug Sabirnetug is a monoclonal antibody designed to selectively bind toxic amyloid-beta oligomers while limiting...

Recent company news

ABOSAcumen Pharmaceuticals2026-10-22 11:30 EST

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

ABOSAcumen Pharmaceuticals2026-10-19 20:00 EST

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

ABOSAcumen Pharmaceuticals2026-09-10 20:00 EST

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

ABOSAcumen Pharmaceuticals2026-09-02 20:00 EST

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

ABOSAcumen Pharmaceuticals2026-08-12 11:00 EST

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

Stock data

Close
2.03 USD
Market cap
171.18M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States